Search Results
Oct 23, 2025, 08:15 ET Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes
the underlying inflammatory biology of the disease. About Ofirnoflast (HT-6184) Ofirnoflast (HT-6184) is Halia Therapeutics' lead investigational compound and a first-in-class NEK7 modulator that regulates activation
More news about: Halia Therapeutics
Oct 22, 2025, 08:00 ET Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
groups, SSRIs/SNRIs and other non-HT (gabapentin, oxybutynin). No statistically significant improvements were seen in WASO, sleep efficiency or sleep latency in the SSRIs/SNRIs group. Statistically significant improvements were seen in WASO at all time points in the other non-HT group. Furthermore,
More news about: Astellas Pharma Inc.
Oct 21, 2025, 19:07 ET RIVANNA awarded $3 million CDMRP grant to develop military-optimized ultrasound guidance system for spinal interventions
Affairs endorsed by the Department of Defense, in the amount of $3 million through the Peer Reviewed Medical Research Program under Award Number HT94252510463. Opinions, interpretations, conclusions, and recommendations are those of the author(s) and are not necessarily endorsed by The Assistant Secretary
More news about: RIVANNA
Oct 21, 2025, 13:37 ET Greenworks® Commercial Expands OPTIMUS Crew for 2026 with Next-Generation Battery Technology, Robotics, and Advanced Tools
Curved Shaft Edger – 8" cutting depth, 2-speed variable trigger, magnesium baseplate for durability, and ergonomic design. HT401SC Hedge Trimmer – 40" single-sided hedge trimmer with patented Quick-Cut™ system, delivering up to 5000 SPM and anti-jam functionality for cleaner,
More news about: Greenworks Commercial
Oct 21, 2025, 09:20 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
serotonin inverse agonist targeting 5-HT2A receptors for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company's robust pipeline demonstrates progress beyond NUPLAZID, with ACP-204 representing a novel 5-HT2A inverse agonist/antagonist advancing
More news about: Equity Insider
Oct 21, 2025, 08:23 ET Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
HOTH) today highlighted FDA Orphan Drug Designation for HT-KIT and new preclinical data demonstrating >80% suppression of KIT expression and significant tumor-volume reduction by Day 8 in systemic mastocytosis and GIST models. HT-KIT, a precision antisense oligonucleotide (ASO) targeting KIT mRNA,
More news about: Hoth Therapeutics, Inc.
Oct 20, 2025, 16:10 ET MATSON TO ANNOUNCE THIRD QUARTER 2025 RESULTS ON NOVEMBER 4, 2025
4:30 p.m. ET / 1:30 p.m. PT / 11:30 a.m. HT
More news about: Matson, Inc.
Oct 17, 2025, 09:38 ET GAC lance sa marque et ses nouveaux modèles au Portugal, marquant ainsi une étape importante dans son expansion européenne.
étape importante pour GAC INTERNATIONAL dans son entrée sur le marché européen. Avec l'AION V commercialisée à partir de 29 990 € HT (IVA), l'arrivée de GAC au Portugal représente bien plus qu'un lancement sur le marché : elle témoigne de la volonté de la marque de façonner l'avenir
More news about: GAC
Oct 17, 2025, 09:00 ET AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD). This next-generation 5-HT2A receptor agonist is designed to help address
More news about: AbbVie
Oct 16, 2025, 14:02 ET Alamar Biosciences élargit son équipe de direction pour assurer la prochaine phase de croissance
protéomique de précision afin de permettre la détection précoce des maladies. La plateforme propriétaire NULISA™ de la société ainsi que le système ARGO™ HT fonctionnent de manière transparente avec les dernières avancées en génomique pour atteindre une sensibilité de détection attomolaire à un chiffre, dépassant
More news about: Alamar Biosciences, Inc.
Oct 16, 2025, 14:01 ET Alamar Biosciences erweitert die Führungsspitze für die nächste Wachstumsphase
Präzisionsproteomik voranzutreiben, um die frühestmögliche Erkennung von Krankheiten zu ermöglichen. Die firmeneigene NULISA™ Platform und das ARGO™ HT System greifen nahtlos mit den neuesten Fortschritten in der Genomik ineinander, um eine Nachweisempfindlichkeit im einstelligen Attomolbereich zu erreichen,
More news about: Alamar Biosciences, Inc.
Oct 16, 2025, 14:00 ET Alamar Biosciences amplía su liderazgo ejecutivo para impulsar la siguiente fase de crecimiento
es impulsar la proteómica de precisión para la detección temprana de enfermedades. Su plataforma NULISA™, propiedad de la compañía, y el sistema ARGO™ HT se integran a la perfección con los últimos avances en genómica para lograr una sensibilidad de detección attomolar de un solo dígito, superando ampliamente
More news about: Alamar Biosciences, Inc.
Oct 16, 2025, 13:59 ET Alamar Biosciences расширяет руководящий штат для обеспечения следующего этапа роста
использования прецизионной протеомики для выявления заболевания на самых ранних стадиях. Запатентованная компанией платформа NULISA™ вместе с системой ARGO™ HT позволяют бесшовно работать с последними достижениями в области геномики для достижения чувствительности обнаружения при исключительно низких концентрациях
More news about: Alamar Biosciences, Inc.
Oct 16, 2025, 13:58 ET Spoločnosť Alamar Biosciences rozširuje svoje výkonné vedenie, aby zvládla ďalšiu fázu rastu
biologických vied, ktorej poslaním je podporovať presnú proteomiku, s cieľom odhaľovať choroby čo najskôr. Patentovaná platforma NULISA™ spolu so systémom ARGO™ HT plynulo spolupracuje s najnovšími pokrokmi v genomike a dosahuje jednocifernú citlivosť atomolárnej detekcie, čím výrazne prevyšuje najcitlivejšiu technológiu
More news about: Alamar Biosciences, Inc.
Oct 16, 2025, 13:57 ET Alamar Biosciences poszerza skład zespołu zarządczego, aby przejść na kolejny etap rozwoju
tworzenie rozwiązań na potrzeby proteomiki celowanej umożliwiającej jak najwcześniejsze wykrywanie chorób. Jej autorska platforma NULISA oraz system ARGO™ HT bazują na aktualnej wiedzy w obszarze genomiki, zapewniając czułość detekcyjną na poziomie jednocyfrowych attomoli, a więc znacznie wyższą niż dostępne
More news about: Alamar Biosciences, Inc.
Oct 16, 2025, 13:55 ET Alamar Biosciences rozšiřuje výkonné vedení pro další fázi růstu
přírodních věd, která si za své poslání zvolila přesnou proteomiku pro včasnou detekci onemocnění. Její proprietární platforma NULISA™ a systém ARGO™ HT dokonale kooperují s nejnovějšími pokroky v genomice a dosahují detekční citlivosti v řádu attomolů, což výrazně předčí nejcitlivější technologie pro
More news about: Alamar Biosciences, Inc.
Oct 16, 2025, 09:25 ET 十五運會香港賽區賽事用車正式交付！廣汽7×24小時服務護航盛會
10月15日，第十五屆全國運動會和全國第十二屆殘疾人運動會暨第九屆特殊奧林匹克運動會香港賽區賽事用車交付儀式在香港中山紀念公園體育館盛大舉行。憑借豐富的「右舵車」制造經驗和在香港市場的全面布局，廣汽為香港賽區提供了符合當地右舵駕駛需求的全球化定制車型，包括90台E9 PHEV和180台HYPTEC HT。同時，為應對賽事24小時高強度運轉的復雜用車需求，廣汽特別為香港賽區設立了廣汽全運會智行保障中心，助力十五運會和殘特奧會順利進行。作為低碳、綠色、智能的美好移動生活價值創造者，廣汽將攜手十五運會為粵港澳大灣區高質量發展和汽車強國建設貢獻更多廣汽力量。
More news about: GAC
Oct 15, 2025, 09:12 ET Alamar Biosciences Expands Executive Leadership to Power Next Phase of Growth
a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive
More news about: Alamar Biosciences, Inc.
Oct 15, 2025, 09:12 ET Alamar Biosciences Expands Executive Leadership to Power Next Phase of Growth
a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive
More news about: Alamar Biosciences, Inc.
Oct 15, 2025, 06:56 ET Team Adventure X Arunachal Pradesh Clinches Runner-Up at the Rally of Himalayas
each obstacle with focus, resilience, and unshakable teamwork. The Toyota Hilux, fitted with JK Tyre's high-performance Ranger HT (265/60R18) SUV tyres, delivered the reliability and performance essential for such extreme conditions. The vehicle's strength and stability, paired
More news about: JK Tyre Motorsport
Oct 14, 2025, 20:00 ET Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
evaluate, in a real-world setting, both the changes in the impact VMS among women beginning non-hormonal therapy (non-HT) for VMS and the effects on work productivity for women initiating non-HT to manage these symptoms. These results highlight Astellas' commitment to expanding clinical knowledge about VEOZAH
More news about: Astellas Pharma Inc.
Oct 13, 2025, 02:18 ET Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies
possible." Bexicaserin (LP352) is a novel investigational, oral therapy that selectively targets the 5-HT2C receptor while avoiding activity at the 5-HT2B and 5-HT2A subtypes, a profile designed to reduce cardiovascular risk. The medicine has also been granted BTD by the U.S. Food and
More news about: H. Lundbeck A/S
Oct 10, 2025, 15:31 ET Alamar Biosciences Luncurkan NULISAqpcr™ BD-pTau217 Assay: Terobosan Deteksi Biomarker Non Invasif Khusus Otak Untuk Penelitian Penyakit Alzheimer
penelitian penemuan maupun penelitian translasi. Alur kerja otomatis pada uji ini memungkinkan pemrosesan lebih dari 220 sampel per hari dengan ARGO™ HT System sehingga ideal untuk analisis throughput tinggi dalam kelompok penyakit atau penelitian terhadap populasi. Alamar Biosciences
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:33 ET Alamar Biosciences запускает анализ NULISAqpcr™ BD-pTau217 -- Прорывное достижение в неинвазивных методах обнаружения специфических биомаркеров мозга для исследований болезни Альцгеймера
и трансляционные исследования. Автоматизированная рабочая процедура анализа позволяет обрабатывать свыше 220 образцов в день с помощью системы ARGO™ HT, что делает его идеальным для высокопроизводительного анализа в когортах заболеваний или популяционных исследованиях. Alamar Biosciences
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 14:11 ET Společnost Alamar Biosciences uvádí na trh test NULISAqpcr™ BD-pTau217: průlom v neinvazivní detekci biomarkerů specifických pro mozek v rámci výzkumu Alzheimerovy choroby
podpoří jak objevný, tak translační výzkum. Automatizovaný pracovní postup testu umožňuje zpracování více než 220 vzorků denně pomocí systému ARGO™ HT, což jej činí ideálním pro vysoce výkonnou analýzu v kohortách pacientů nebo populačních studiích. Společnost Alamar Biosciences
More news about: Alamar Biosciences, Inc.